Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05789056 PHASE2, PHASE3 RECRUITING

To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome

Details

Lead sponsor	Quoin Pharmaceuticals
Phase	PHASE2, PHASE3
Status	RECRUITING
Enrolment	20
Start date	Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Netherton Syndrome

Interventions

• QRX003, 4% Lotion

Countries

United States